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Abstract
Aim
We describe the effectiveness and safety of the interferon-free regimen ombitasvir/parita-
previr/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ±DSV ± RBV) in a
nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human
immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.
Material and methods
Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1
coinfection, treated with OBV/PTV/r ±DSV ±RBV at 61 Spanish sites within the initial imple-
mentation year of the first government-driven “National HCV plan.” Effectiveness was
assessed by sustained virologic response at post-treatment week 12 (SVR12) and com-
pared between monoinfected and coinfected patients using a non-inferiority margin of 5%
and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or
patients and adverse events (AEs) were also recorded.
Results
Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were
patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in
each participating region in Spain. From the total population, 96.6% (95% CI, 95.8–97.3%)
achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference
between monoinfected and coinfected patients of −2.2% (90% CI, −4.5% - 0.2%). Only
genotype 4 was associated with non-response to OBV/PTV/r ±DSV ± RBV treatment
(p<0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs poten-
tially related to OBV/PTV/r ±DSV, whereas 347 (29.0%) presented AEs potentially related
to ribavirin and 61 (5.1%) interrupted ribavirin.
Conclusions
Our results confirm that OBV/PTV/r ± DSV ±RBV is effective and generally well tolerated in
a representative sample of the HCV monoinfected and HCV/HIV coinfected population in
Spain within the experience of a national strategic plan to tackle HCV.
Real-world evidence on chronic hepatitis C in Spain
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Introduction
In 2015, when this study was initiated, it was estimated that 71 million individuals were living
with hepatitis C virus (HCV) infection worldwide, more than 2.2 million of whom were
believed to be coinfected with human immunodeficiency virus (HIV)[1]. According to the
World Health Organization, globally, approximately 71 million people have HCV infection [2].
In Europe, the prevalence of HCV ranges from 0.1% in Belgium, Ireland, and the Netherlands
to 5.9% in Italy, while for Spain, the latest serologic survey estimates the overall prevalence of
anti-HCV at approximately 1.1% of the Spanish population [3], lower than previously reported
[4]. Notably, only 41% anti-HCV cases had positive HCV-RNA [3]. Most infections are caused
by genotypes (GT) 1a, 1b, 2, 3 (almost exclusively 3a) and 4 [5]. Genotype 1b is the most preva-
lent (42.4%) in Spain, followed by 1a (22.5%), 3 (18.6%), 4 (10.6%) and 2 (4.6%) [6]. Coinfection
with HIV is one of the most common comorbidities in patients with HCV [7]. In 2016, the
prevalence of HCV in patients infected with HIV in Spain was 34.6% and, unlike HCV monoin-
fected patients, the most prevalent GTs in this population were GT1a and GT4 [8].
HCV infection can lead to many long-term complications. Most patients (80%–85%) who
become acutely HCV-infected or HIV/HCV-coinfected progress to chronic HCV infection,
and are at risk of developing cirrhosis, portal hypertension, hepatic decompensation and hepa-
tocellular carcinoma[9]. Treating HCV infection prevents the progression of hepatic fibrosis
to cirrhosis and the aforementioned complications, even with initial treatments based on
peginterferon (peg-IFN) and ribavirin [9].
Interferon-free direct-acting antiviral agents (DAAs) have shown high effectiveness against
HCV infection, with sustained virologic response (SVR) rates above 90% [10, 11]. Accordingly,
they have become the new standard of care in patients with chronic HCV infection [10, 11].
The DAA combination of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without
ribavirin (OBV/PTV/r ± DSV ± RBV) has shown favorable efficacy and tolerability in clinical
studies [12–16].
In 2015, health authorities in Spain launched the first “National HCV Plan” to provide
guidelines on the treatment of patients with already-diagnosed chronic HCV infection, which
was designed to be implemented over the course of 3 years. According to this strategic plan, all
patients with chronic HCV infection, whether monoinfected or coinfected with HIV, or
whether they were treatment-naïve or had not responded to a prior antiviral treatment, were
considered candidates for antiviral treatment. This treatment freely accessed by all patients
insured under the Spanish National Health System.
Most HCV patients identified at that time were treated within the first year—between 2015
and 2016[17]. This plan was contemporaneous with the approval and market launch of OBV/
PTV/r and DSV in Spain in April 2015 (Viekirax1, AbbVie Inc., North Chicago, IL, and
Exviera1, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, respectively)[18,
19] to treat patients with chronic HCV GT1 and GT4 infections, regardless of HIV coinfection
status [10, 11, 20]. Viekirax1 [18] contains PTV/r and OBV. PTV is an inhibitor of HCV
NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polypro-
tein and is essential for viral replication. OBV is administered with ritonavir (r), a potent
CYP3A4 inhibitor used as a pharmacokinetic enhancer in order to achieve efficacious expo-
sures. Exviera1 [19], on the other hand, contains DSV, a non-nucleoside inhibitor of the
HCV RNA-dependent RNA polymerase encoded by the NS5B gene.
This study included patients who had started treatment within the first year following the
approval of Viekirax1 and Exviera1, and within the strategic plan for tackling HCV infection
among residents in Spain universally treated by the Spanish National Health System. Prelimi-
nary real-world data with coexisting IFN-free DAAs have shown high rates of SVR in Spanish
Real-world evidence on chronic hepatitis C in Spain
PLOS ONE | https://doi.org/10.1371/journal.pone.0225061 November 12, 2019 3 / 18
Gallego, Marta Magaz, A´ngel Este´banez, Mikel
Rico, Blanca Sampedro, Sonia Izquierdo, Jose´
Manuel Zozaya, Senador Mora´n-Sa´nchez, Ignacio
Martı´n-Granizo, Marcial Delgado declare no conflict
of interest. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
patients monoinfected with HCV GT1, as observed in registrational clinical trials[21, 22].
However, important subgroups of patients, such as those with HIV coinfection or GT4, were
not included in these studies. The aim of this study was to describe the effectiveness and safety
of the IFN-free OBV/PTV/r ± DSV ± RBV regimen in a large nationwide representative sam-
ple of the HCV monoinfected and HIV/HCV coinfected populations in Spain.
Materials and methods
Study design and patients
A non-interventional, retrospective, national, multicenter study was designed, with the partici-
pation of 61 sites in 48 hospitals distributed across all administrative regions of Spain (includ-
ing 48 gastroenterology departments and 13 internal medicine/infectious diseases
departments). The participating sites were public hospitals, located in any region of Spain,
thus ensuring a heterogeneous patient sample and reducing the likelihood of a biased study
population. Sites were selected taking into consideration the patient population under study
and requirements to reach the weighted sample size per region. The information is listed in S1
Table, by regions, centers/sites/departments and specialties. S1 Table also includes the com-
plete list of the centres which have contributed to the study.
Data were collected after a review of databases and medical records of adult patients with
confirmed chronic HCV GT1 or GT4 infection, any stage of fibrosis, HCV monoinfection or
HIV-1/HCV coinfection who had been treated with OBV/PTV/r ± DSV ± RBV. The decision
to treat and the choice of treatment, including treatment duration and the use or not of con-
comitant RBV, had been at the discretion of the treating physician in the context of routine
medical care. Patients included had initiated treatment from April 2015 to March 2016 and
had ended it (complete treatment or premature termination) by June 2016. All HCV viral load
determinations at week 12 after the end of treatment (or the last visit in case of rebound) had
been performed by September 2016. Patients with hepatitis B coinfection, decompensated cir-
rhosis or who had participated in a concurrent interventional therapeutic trial while on treat-
ment or 12 weeks after treatment with OBV/PTV/r ± DSV ± RBV were excluded.
The institutional review boards of all but three participating sites exempted the investiga-
tors from obtaining patient consent forms because the study was fully retrospective and had a
short period of anonymous data collection. In the three sites where consent was required,
informed consent was obtained in writing. No information identifying patients was captured.
The study was approved by the Spanish Agency of Medicinal Products and Medical Devices
(code ABB-OMD-2016-01) and obtained its first approval by the Ethic Committee of the Hos-
pital la Princesa, Madrid with data 21 of July 2016. The study was presented to evaluation and/
or notification to the rest of Ethic Committees of the hospitals involved, depending of the
requirements of each center. The independent Ethic Committees that evaluated the study are
listed in S1 Supporting information.
Outcome-related variables
Sociodemographic variables, clinical characteristics of HCV infection, medical history, previ-
ous HCV therapy, HCV RNA count and laboratory tests, characteristics of the study treatment
and adverse events (AEs) were collected. As this is an observational study, each treating physi-
cian followed standard clinical practice and verified that concomitant medication could be
safely administered with the DAA regimen (including ritonavir) and RBV. Some medications
were contraindicated and some required dose adjustments due to potential drug-drug
interactions.
Real-world evidence on chronic hepatitis C in Spain
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Sustained virologic response at week 12 (SVR12)
Treatment effectiveness was measured by the percentage of patients achieving SVR12, defined
as an HCV RNA below the lower limit of quantification or detection 12 weeks (70 to 126 days)
after treatment completion. HCV RNA levels were determined using real-time polymerase
chain reaction based on either the Roche COBAS TaqMan HCV or the Abbott RealTime HCV
polymerase chain reaction assays. Patients were considered responders if HCV RNA was
undetectable (lower limit of quantification or detection�50 IU/mL) or unquantifiable (lower
limit of quantification�50 IU/mL). Virologic response was also assessed at the end of treat-
ment (EoT).
To analyze the difference in SVR12 rates between patients with monoinfection and coinfec-
tion, both rates were compared assuming a non-inferiority margin of 5% (based on scientific
discussion with researchers and clinicians) with a 90% confidence interval (CI) (Farrington-
Manning method).
Sample size estimation and control of inclusion bias
In the context of the strategic plan by the Spanish National Health System for tackling HCV
[17], approximately 12 900 patients with HCV and HIV/HCV infections initiated treatment
with PTV/r/OBV ± DSV ± RBV from April 2015 to March 2016. Expected effectiveness was
estimated to be>90%, and a sample of 2,500 patients was considered sufficient to be represen-
tative of the population and to ensure an SVR12 rate precision of approximately 1.2%. To
ensure a sample that is representative of the Spanish HCV scenario, the number of patients to
be included from each administrative region was weighted to the proportion of patients who
started treatment in that region during the defined period. After weighting, each participating
site had an allotted number of patients to include, who were then randomly selected from their
internal list of treated patients that fulfilled the inclusion criteria. If an institution had two par-
ticipating departments (eg, hepatology, internal medicine), each unit had its own allotted
number of patients to enroll and drew up an independent list of patients for random inclusion.
Each confidential list was ordered chronologically per treatment start date, and an indepen-
dent statistician provided each center or department with the randomly selected positions of
the cases to include in the electronic Case Report Form.
Statistical analysis
Qualitative variables were summarized in a table that included absolute and relative frequen-
cies per group and in the whole population (column percentages, if no other specifications
were detailed). Quantitative variables were provided using number of valid cases, mean, stan-
dard deviation, median, interquartile range, minimum, and maximum.
Quantitative parameters without a normal distribution and ordinal parameters were com-
pared using a non-parametric Mann-Whitney test for two categories and Kruskal-Wallis test
for three or more categories. Qualitative parameters were analyzed using a χ2 test or, if
assumptions were not met, Fisher’s exact test.
The significance level in bivariate analysis was generally established at a value of α = 0.05.
Quantitative variables were compared between groups using a two-sample t test (when two
groups were compared) and analysis of variance when three or more groups were compared.
In cases where the analysis of variance test showed a significance level<0.05, the post hoc Bon-
ferroni test was used at a significance level of 0.01 to detect differences in pairwise
comparisons.
Univariate and multiple logistic regression was used to investigate the impact of the follow-
ing explanatory covariates (patient and disease characteristics) at baseline on SVR12: HIV/
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HCV coinfection; demographic information (age, sex, ethnicity, body mass index, and IL28B
polymorphism rs12979860); chronic HCV disease characteristics; HCV RNA level at baseline;
HCV genotype/subtype; coinfections (HIV and HBV); comorbidities related or unrelated with
the liver and chronic HCV; other comorbidities; alcohol use; clinical chemistry and hematol-
ogy variables at baseline (alanine transaminase [ALT]/aspartate transaminase [AST] ratio,
platelets, albumin and creatinine); in treatment-experienced patients (most recent previous
treatment for chronic HCV and its outcome); OBV/PTV/r ± DSV ± RBV use (according or
not to local label); and treatment adherence.
Results
Patient demographics and clinical characteristics at baseline
A total of 2,465 patients were registered from 61 sites across Spain, and 2,408 were included in
the analysis as the core evaluable population fulfilling selection criteria: 2,022 patients with
HCV and 386 patients HIV/HCV. Among coinfected patients, CD4 T-cell count was over 500
cells/mm3 in 63.2% (N = 244) at baseline and HIV-RNA was undetectable in 79.0% (N = 304).
During follow-up, 65.3% (N = 252) of HIV coinfected patients achieved a CD4 count over 500
cells/mm3, while 81.8% of patients had undetectable HIV-RNA levels.
Patient selection reflected the real distribution of patients treated with OBV/PTV/r ± DSV
± RBV in each region in Spain. (S2 Table).
Table 1 shows the demographic and clinical characteristics of patients with chronic HCV
included at baseline (n = 2,408); for the overall population, mean (SD) age was 57.8 (11.6)
years and 59.8% were male. The mean duration of the disease was 15.7 (9.0) years. The most
frequent genotype was GT1b (68.2%), followed by genotypes GT1a (19.0%) and GT4 (12.1%).
The following differences were observed between patients with HIV/HCV and those with
HCV: patients with HIV/HCV were predominantly males (78.5% vs. 56.3%) and younger
(33.4% of HIV/HCV patients were<50 years vs. 20.5% of HCV patients, p<0.001 age distribu-
tion). Additionally, only 35.7% vs. 45.3% of patients with HIV/HCV vs. HCV, respectively,
were overweight (body mass index >25–30 kg/m2). Most patients in both groups were GT1
(HIV/HCV, 71.2%; HCV, 91.0%). However, the distribution of the sub-genotypes was differ-
ent for each population, as follows: GT1b was more frequent in patients with HCV (76.4%),
whereas GT1a was predominantly detected in patients with HIV/HCV (44.8%).
Most patients (92.7%) had the fibrosis grade determined by non-invasive methods (96%
using transient elastography, Fibroscan1, EchoSens, Paris, France), and biopsy data were pro-
vided in 88 patients (3.7%). Cirrhosis was reported based on invasive/non-invasive methods
and clinical guess in 873 patients (36.3%), and 7 cirrhotic patients (0.8%) had a Child-Pugh
Score class B (7–9 points). See Table 1 for further details.
All patients (n = 2,408) had the HCV RNA quantification performed a mean of 17.7 weeks
before the beginning of treatment. The mean HCV RNA at baseline was 2,962,193 IU/mL, and
67.6% of patients had HCV RNA higher than 800 000 IU/mL. A higher percentage of patients
with HIV/HCV than HCV showed HCV RNA over 800 000 IU/mL (71.5 vs. 66.9, p = 0.074).
Mean (SD) laboratory values for patients with HCV (n = 1,970) and HIV/HCV (n = 384)
were 98.3 (34.9) mL/min vs. 100.8 (30.9) mL/min for creatinine clearance and 89.5 (21.9) mL/
min/1.73m2 vs. 93.2 (20.8) mL/min/1.73m2 for estimated glomerular filtration rate (eGFR),
respectively.
Sixty-two percent of patients (n = 1,498) presented comorbidities (HCV: 62.9%; HIV/HCV:
58.5%), the most prevalent being cardiovascular diseases (30.4%), diabetes (14.2%) and psychi-
atric disorders (11.8%). Accordingly, 1,614 patients took concomitant medication (33% car-
diovascular drugs, 29% alimentary drugs [mainly antacids] and 29% nervous system drugs).
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Table 1. Demographic and clinical characteristics of patients with Chronic HCV and HIV/HCV treated With OBV/PTV/r ± DSV ± RBV.
Variable HCV HIV/HCV Total
N = 2,408�
Department, n (%)
Gastroenterology 1,981 (98.0) 25 (6.5) 2,006 (83.3)
Infectious diseases 41 (2.0) 361 (93.5) 402 (16.7)
Sex, male, n (%) 1,138 (56.3) 303 (78.5)† 1,441 (59.8)
Age, mean (SD), y 59.1 (11.9) 50.8 (6.4)† 57.8 (11.6)
<50 y, n (%) 415 (20.5) 129 (33.4)†§ 544 (22.6)
�50 y, n (%) 1,607 (79.5) 257 (66.6) 1,864 (77.4)
White ethnicity, n (%) 1,992 (98.5) 366 (95.6)†§ 2,358 (98.0)
No alcohol consumption��, n (%) 1,525 (76.2) 278 (72.0) 1,803 (75.5)
BMI, mean (SD), Kg/m2 26.60 (4.1) 24.50 (3.8)† 26.1 (4.1)
BMI group, overweight, (BMI = 25−30 Kg/m2), n (%) 463 (45.3) 117 (35.7) 580 (43.0)
IL-28, genotype CC (SNP rs12979860), n (%) 201 (22.4) 83 (36.2)† 284 (25.2)
Duration of chronic HCV���, mean (SD), y 15.21 (9.1) 18.2 (8.2)† 15.7 (9.0)
HCV genotype, n (%)
GT1 1,841 (91.0) 275 (71.2)†§ 2,116 (87.9)
GT1a 284 (14.0) 173 (44.8) 457 (19.0)
GT1b 1,544 (76.4) 99 (25.6) 1,643 (68.2)
GT1 others 13 (0.6) 3 (0.8) 16 (0.7)
GT4 181 (9.0) 111 (28.8) 292 (12.1)
HCV RNA Quant-Test result, mean (SD), IU/mL 2 793 122.7
(4 301 803.4)
3 849 702.9
(5 999 880.7)
2 962 193.1
(4 630 442.9)
HCV RNA/Quant-Test, n (%)
Abbott Real-Time HCV (RT-PCR) 443 (21.9) 53 (13.7) 496 (20.6)
Roche COBAS TaqMan HCV 1,252 (61.9) 203 (52.6) 1,455 (60.4)
HCV RNA Quant-Test result (global), n (%)
Low HCV RNA (�800 000 IU/mL) 670 (33.1) 110 (28.5) 780 (32.4)
High HCV RNA (>800 000 IU/mL) 1,352 (66.9) 276 (71.5) 1,628 (67.6)
Cirrhosis,���� n (%) 742 (36.7) 131 (33.9) 873 (36.3)
Cirrhosis (F4) per fibrosis grade method, n (%)
Tested by Fibroscan1 (F4) n = 1860
631 (33.9)
n = 373
123 (33.0)
n = 2,233
754 (33.8)
Biopsy (F4) n = 81
30 (37.0)
n = 7
1 (14.3)
n = 88
31 (35.2)
Fibroscan1 (categorized),����� n (%)
<8.8 kPa 613 (34.5) 130 (35.7) 743 (34.7)
8.8−< 9.6 kPa 146 (8.2) 27 (7.4) 173 (8.1)
9.6−< 12.5 kPa 386 (21.7) 74 (20.3) 460 (21.5)
12.5−< 14.6 kPa 153 (8.6) 31 (8.5) 184 (8.6)
14.6−< 20.0 kPa 181 (10.2) 44 (12.1) 225 (10.5)
>20.0 kPa+ 298 (16.8) 58 (15.9) 356 (16.6)
Child Pugh Score, n (%)
Class A (5−6) 713 (99.3) 119 (98.3) 832 (99.2)
Class B (7−9) 5 (0.7) 2 (1.7) 7 (0.8)
HIV infection, n (%) — 386 (100) 386 (16)
Duration of HIV infection, mean (SD), y — 21.9 (70) 21.9 (70)
ALT, mean (SD), IU/L 79.9 (60.5) 73.5 (61.4)‡ 78.9 (60.6)
AST, mean (SD) IU/L 67.1 (46.5) 61.7 (40.6) 66.2 (45.7)
(Continued)
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Patients with HIV/HCV received the following anchor antiretroviral therapies for the HIV
infection: integrase inhibitors (41.2%), protease inhibitors (37.3%) or non-nucleoside reverse
transcriptase inhibitors (13.74%).
Previous treatment for HCV infection
A total of 1,025 patients (42.6%) were previously treated for HCV, the most frequent combina-
tions being IFN or peg-IFN + RBV (81.0%). In addition, 42 patients (4.1%) had also received
DAAs, as follows: 42.9% telaprevir, 21.4% boceprevir and 16.7% simeprevir. More than 40% of
previously treated patients (HCV: 43.6%; HIV/HCV: 40.9%) were null responders, 22.1% had
Table 1. (Continued)
Variable HCV HIV/HCV Total
N = 2,408�
Total bilirubin, mean (SD), mg/dL 0.8 (0.5) 0.76 (0.5) 0.8 (0.5)
Hemoglobin, mean (SD) g/L 147.4 (16.5) 151.6 (15.8) 148.1 (16.5)
Platelets, mean (SD), ×109/L 174.8 (67.9) 167.1 (63.6) 173.5 (67.2)
eGFR, mean (SD), mL/min/1.73m2��� 89.5 (21.9) 93.2 (20.8) 90.1 (21.7)
Creatinine clearance, mean (SD), mL/min��� 98.3 (34.9) 100.8 (30.9) 98.7 (34.3)
Most likely mode of HCV infection
Drug use (i.v.) 192 (9.5) 305 (79.0) 497 (20.6)
Drug use (non i.v.) 18 (0.9) 2 (0.5) 20 (0.8)
Occupational� 25 (1.2) 25 (1.0)
Blood transfusion or transplantation 398 (19.7) 3 (0.8) 401 (16.7)
Perinatal 25 (1.2) 1 (0.3) 26 (1.1)
Contaminated medical device (other than i.v. drug use) 83 (4.1) 83 (3.4)
Heterosexual transmission 11 (0.5) 23 (6.0) 34 (1.4)
Homosexual transmission (MSM) 2 (0.1) 30 (7.8) 32 (1.3)
Other 29 (1.4) 29 (1.2)
Unknown 1239 (61.3) 22 (5.7) 1261 (52.4)
ART at baseline visit 357 (92.5) 357 (14.8)
Nucleosides and nucleotides excl. reverse transcriptase inhibitors 3 (0.8) 3 (0.1)
Protease inhibitors 144 (37.3) 144 (5.9)
Nucleoside and nucleotide reverse transcriptase inhibitors 98 (25.4) 98 (4.1)
Non-nucleoside reverse transcriptase inhibitors 52 (13.5) 52 (2.2)
Antivirals for treatment of HIV infections, combinations 223 (57.8) 223 (9.3)
Other antivirals 165 (42.7) 165 (6.9)
Abbreviations: ALT, alanine transaminase; APRI, aspartate transaminase to platelet ratio index; ART, Antiretroviral treatment; AST, aspartate transaminase; BMI, body
mass index; eGFR, estimated glomerular filtration rate; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OBV/PTV/r ± DSV ± RBV,
ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin; SNP, single nucleotide polymorphism.
† p<0.0001;
†§ p<0.001 per distribution category;
‡ p = 0.0019.
� Not all patients had available data for all parameters.
��No alcohol consumption refers to the number of patients who reported that they were not consuming alcohol at that time of the study nor in the past.
���Duration of chronic HCV refers to the time from diagnosis of chronic HCV infection to the time of the study.
���� Cirrhosis level checked by the investigator based on invasive and/or non-invasive methods and clinical criteria. Regarding Fibroscan1 levels, most patients were
considered as having fibrosis stage F4 (�12.5 kPa) (n: 632 [35.6%] monoinfected, 133 [35.5%] coinfected and 765 [35.3%] of the total cases, respectively).
����� For renal function, creatinine clearance and eGFR were calculated by imputing mean weight in missing cases (77.3 Kg for men and 66.0 Kg for women).
https://doi.org/10.1371/journal.pone.0225061.t001
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relapsed (HCV: 21.8% and HIV/HCV: 23.9%), 12.6% had partial response (HCV: HCV: 12.9%
and HIV/HCV: 10.7%) and finally, 2.1% had breakthrough (HCV: 1.7% and HIV/HCV:
4.4%).
Treatment regimen and duration
Overall, most patients (79.5%) received 12 weeks of OBV/PTV/r + DSV treatment, with (31%)
or without (48.5%) concomitant ribavirin, followed by an OBV/PTV/r regimen for 12 weeks
(9.1%) and adding ribavirin (8.1%). The remaining patients received treatment for 24 weeks
(11.3%). The treatment regimen was adjusted according to the patient’s genotype and cirrhosis
status (Table 2): OBV/PTV/r + DSV 12 weeks was the most frequent in GT1b without cirrhosis
(91%), whereas most patients with GT1b with compensated cirrhosis had OBV/PTV/r + DSV
plus ribavirin for 12 weeks (64%). Moreover, most patients with GT4 without cirrhosis
received OBV/PTV/r + RBV for 12 weeks (84.8%). For patients with GT4 and compensated
cirrhosis, the most common treatment duration was 24 weeks. The planned study regimen for
most patients with HCV was OBV/PTV/r + DSV ± RBV for 12 weeks (84.6%) (only 36.3%
added ribavirin). For patients with HIV/HCV, 53.1% were eligible for OBV/PTV/r
+ DSV ± RBV for 12 weeks and the addition of ribavirin (61.0%). Overall, a total of 218
patients with HCV (9.1%) were treated off-label, that is, with OBV/PTV/r ± DSV ± RBV regi-
mens different from those included on the label or national guidelines (Table 2). Notably,
those off-label patients included 20.3% of the 74 patients with HCV GT4 and compensated
cirrhosis.
For treatments with a planned duration of 12 weeks, the real duration was within 1 week of
that planned in 96.2% of patients. In the case of 24 weeks, 89.0% of patients with HCV had a
Table 2. Selected treatment regimens.
Treatment Regimen GT1b
n = 1,654, n (%)
GT1a
n = 455, n (%)
GT4
n = 291, n (%)
Other,
n (%)
n = 11
Total, n (%)
N = 2,408
Without
Cirrhosis
n = 1,037
With
Compensated
Cirrhosis�
n = 614
Without
Cirrhosis
n = 278
With
Compensated
Cirrhosis
n = 177
Without
Cirrhosis
n = 217
With
Compensated
Cirrhosis
n = 74
Regimen
received
OBV/PTV/r + RBV 12 weeks 1 (0.2) 1 (0.6) 184
(84.8)
10 (13.5) 196 (8.1)
OBV/PTV/r 12 weeks 18 (1.7) 2 (0.3) 3 (1.4) 1 (1.4) 24 (1.0)
OBV/PTV/r + RBV 24 weeks 1 (0.2) 1 (0.6) 11 (5.1) 59 (79.7) 1 (9.1) 73 (3.0)
OBV/PTV/r + DSV + RBV 12
weeks
66 (6.4) 393 (64.0) 244
(87.8)
23 (13.0) 13 (6.0) 7 (63.6) 746 (31.0)
OBV/PTV/r + DSV 12 weeks 944
(91.0)
205 (33.4) 15 (5.4) 1 (0.6) 4 (1.8) 1,169 (48.5)
OBV/PTV/r + DSV + RBV 24
weeks
3 (0.3) 9 (1.5) 13 (4.7) 150 (84.7) 2 (0.9) 3 (4.1) 3 (27.3) 183 (7.6)
OBV/PTV/r + DSV 24 weeks 6 (0.6) 3 (0.5) 6 (2.2) 1 (0.6) 1 (1.4) 17 (0.7)
On-label
treatment��
Yes 944
(91.0)
598 (97.4) 244
(87.8)
150 (84.7) 184
(84.8)
59 (79.7) 11
(100)
2,190 (90.9)
No 93 (9.0) 16 (2.6) 34 (12.2) 27 (15.3) 33 (15.2) 15 (20.3) 218 (9.1)
Abbreviations: DSV, dasabuvir; GT, genotype; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin.
� Note: Although OBV/PTV/r ± DSV has no indication in patients with decompensated cirrhosis, some patients with decompensated cirrhosis have been included
according to the Child-Pugh Score. Use of OBV/PTV/r + DSV regarding treatment duration and concomitant use of RBV based on approved label is set in bold;
summary per groups is shown here for on- and off-label treatment.
�� The term on-label refers to the treatment that has been administer according to the EU Summary of Product Characteristics (SmPC).
https://doi.org/10.1371/journal.pone.0225061.t002
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similar duration (±1 week). The main reasons for deviating treatment durations were AEs
(23.4%) and other unspecified reasons.
Virologic response
At EoT, a total of 2,333 patients (96.9%) had virologic response, and only 17 had a detectable
viral load. Among the intention-to-treat (ITT) population, 2,327 patients achieved SVR12
(96.6% [95% CI, 95.8−97.3%]). SVR12 was reached by 2,054 of 2,116 patients (97.1%) with
GT1 (GT1a/G1x: 96.2%, GT1b: 97.3%) and 273 of 292 patients (93.5%) with HCV GT4 infec-
tion (Fig 1). When examining per cohort, SVR12 rates were 94.8% (95% CI, 92.1−96.8%) for
patients with HIV/HCV and 97.0% (95%CI: 96.1−97.7%) for patients with HCV. Of the 81
patients (3.4%) who did not achieve SVR12, 44 (1.8%) had virologic failure: 17 relapses, 5
breakthroughs and 22 patients were finally confirmed as null responders (HCV RNA
value� 50 IU/mL). Failure to achieve SVR12 was not associated with virologic reasons
(relapses, breakthroughs or failure to suppress) in 37 patients (45.6%) (S3 Table).
The non-inferiority analysis showed that patients with HIV/HCV had an SVR12 rate within
the non-inferiority margin of 5% from the rate of patients with HCV (−2.2% [90% CI, −4.5%
to 0.2%]).
Table 3 shows SVR12 rates and 95% CIs according to each ITT criterion in patients with
HCV and those with HIV/HCV. Differences in rates between groups ranged from 1.8% to
2.6%.
Multivariable logistic model for SVR12
According to the univariate analysis and considering the ITT population, the following base-
line characteristics were significantly associated with lower SVR12 rates: age (<60 years;
p = 0.01), HIV/HCV coinfection (p = 0.03), genotype 4 (p = 0.001) and prothrombin time >14
seconds (p = 0.008). Nevertheless, the multivariate analysis revealed that only the viral
Fig 1. SVR12 according to genotype (ITT analysis). Abbreviations: GT, genotype; SVR12, sustained virologic response at 12 weeks; ITT, intention-to-treat.
Abbreviations: GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0225061.g001
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genotype was associated with non-response to treatment. GT4 was predictive of non-response
to OBV/PTV/r + DSV ± RBV treatment (odds ratio, 2.6; 95% CI, 1.5–4.6; p<0.001).
Safety
The AEs most frequently reported in the total population (n = 2,408) were anemia (18.6%),
asthenia (13.2%), headache (6.0%), pruritus (5.9%), insomnia (5.2%), nausea (2.9%), diarrhea
(2.8%) and fatigue (2.3%). Treatment-emergent AEs occurred in 24.8% of patients and only
2.0% presented serious AEs.
Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r and PTV/r/
OBV + DSV ± RBV, whereas 347 patients (14.4%) presented AEs potentially-related only to
RBV. As a consequence, 29 patients (1.2%) had to discontinue OBV/PTV/r ± DSV treatment
and 61 (2.5%) had to discontinue RBV. In addition, a decrease in dosage or temporary treat-
ment interruption was proposed for 177 patients (7.4%) because of AEs.
Only 48 patients (2%) presented a serious AE, as follows: 56 serious AEs, including five
hepatocellular carcinoma (0.2%), and eight deaths (0.3%), two considered possibly related to
the study drug (pneumonia lasting 50 weeks and worsening of chronic renal disease)
(Table 4).
The most common AEs related to OBV/PTV/r ± DSV were asthenia (19.4%), headache
(10.0%), insomnia (10.0%) and pruritus (8.6%), while AEs related to RBV were anemia
(37.5%), asthenia (14.4%), pruritus (7.4%), insomnia (4.6%) and rash (3.8%).
Levels of ALT showed a statistically significant decrease at EoT (mean [SD] decrease of 58.4
[61.4] IU/mL) and 12 weeks after EoT (mean [SD] decrease of 57.8 [58.1] IU/mL) compared
with baseline levels (p<0.001). Additionally, a significant decrease (p<0.001) in AST activity
was observed from baseline levels to EoT (mean [SD] decrease of 43.3 [44.1] IU/mL) and 12
weeks after EoT (mean [SD] decrease of 42.3 [42.9] IU/mL). AST/ALT ratio levels showed a
statistically significant decrease at EoT (mean [SD] decrease of 0.8 [0.9] IU/mL) and 12 weeks
after EoT (mean [SD] decrease of 0.8 [0.8] IU/mL) compared with the baseline value.
Conversely, although mean hemoglobin values decreased during the treatment period
(mean of 14.8 g/dL at baseline and 13.7g/dL at EoT), they recovered 12 weeks after EoT (14.7
g/dL). Mean eGFR decreased slightly throughout treatment (90.5 [31.0] mL/min/1.73m2 at
Table 3. SVR12 According to HIV coinfection status (ITT analysis).
HCV
(83.97%)
HIV/HCV
(16.03%)
Total
(100%)
Adjusted Total���
SVR12
Noni-Inferiority
90%IC
ITT 1,961/2,022
(97.0%)
[96.1–97.7%]
366/386
(94.8%)
[92.1–96.8%]
2,327/2,408
(96.6%)
[95.8–97.3%]
96.6%
[95.9–97.3%]
-2.2%
[-4.5% to 0.2%]
mITT1� 1,961/2,009
(97.6%)
[96.8–98.2%]
366/385
(95.1%)
[92.4–97.0%]
2,327/2,394
(97.2%)
[96.5–97.8%]
97.2%
[96.5–97.8%]
-2.6%
[-4.9% to -0.3%]
mITT2�� 1,961/1,994
(98.3%)
[97.7–98.9%]
366/379
(96.6%)
[94.2–98.2%]
2,327/2,373
(98.1%)
[97.4–98.6%]
98.0%
[97.5–98.6%]
-1.8%
[-3.7% to 0.1%]
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; mITT modified intention-to-treat; SVR12, sustained virologic response at 12 weeks.
� ITT modified criteria (mITT1) excludes patients with no response due to loss of follow-up.
�� ITT modified criteria (mITT2) excludes patients with no response due to loss of follow-up and patients with other non-virologic reasons for missing data 70 days
post-treatment.
��� The SVR12 analysis was adjusted according to the estimated proportion of HIV/HCV (82% and 18% of HCV and HIV/HCV patients, respectively).
https://doi.org/10.1371/journal.pone.0225061.t003
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baseline and 89.1 [21.6] mL/min/1.73m2 at EoT) and 12 weeks after EoT (88.2 [21.3] mL/min/
1.73m2).
Discussion
To the best of our knowledge, this study is one of the largest describing the effectiveness of the
OBV/PTV/r ± DSV ± RBV regimen under routine clinical conditions in both patients with
HCV monoinfection and patients with HIV/HCV coinfection. Both cohorts included patients
with HCV GT1 and GT4 infection, cirrhosis and patients who had received previous HCV
treatment. Of note, this study was conducted in the context of a government-driven HCV stra-
tegic plan aimed at reducing the morbidity and mortality caused by HCV in Spain[17], con-
ceived in view of the launch of new DAAs against hepatitis C on the market, including OBV/
PTV/r ± DSV ± RBV[18, 19]. As a result of this national plan, a remarkably large number of
patients with HCV and HIV/HCV started OBV/PTV/r ± DSV ± RBV treatment in 2015, its
first year of implementation. To design a study that adequately reflected the significance and
extent of this approach against hepatitis C, we considered it paramount to apply a distinct
method to recruit a representative sample of patients at a national level. A relevant randomized
sample of patients who were just initiating treatment with OBV/PTV/r ± DSV ± RBV from
April 2015 to March 2016 was therefore selected in each health administration area in Spain.
Thus, we believe our results accurately reflect real clinical practice at this crucial moment and
at a national level.
In the study population, treatment was generally based on the label recommendations for
patients with infection by HCV genotypes 1a, 1b or 4, regardless of HIV-1 status [10, 11, 20].
Only 9.1% of patients with HCV were not treated according to local guidelines. This group did
not include, for instance, patients with GT1b and compensated cirrhosis, treated for 12 weeks
with OBV/PTV/r + DSV but without ribavirin—at that time not yet on the label—based on
already published data from the TURQUOISE III study [14]. Thus, OBV/PTV/r ± DSV based
regimens included on the label after study patients had been treated, but with published clini-
cal trial data, have not been considered off-label. Nevertheless, there were no patients GT1b-
naive treated for 8 weeks with OBV/PTV/r ± DSV.
Table 4. AEs Occurring during treatment or follow-up in patients treated With OBV/PTV/r ± DSV ± RBV.
AE PTV/r/OBV + RBV
n = 269
PTV/r/OBV + DSV + RBV
n = 929
PTV/r/OBV + DSV
n = 1,186
Total
N = 2,408
Any AE 77 (28.6) 338 (36.4) 180 (15.2) 596 (24.8)
Severity 3 (1.1) 19 (2.0) 17 (1.4) 39 (1.6)
Any serious AE� 1 (0.4) 22 (2.4) 25 (2.1) 48 (2.0)
Death 0 3 (0.3) 5 (0.4) 8 (0.3)
AEs related to OBV/PTV/r ± DSV�� 40 (14.9) 127 (13.7) 118 (9.9) 286 (11.9)
OBV/PTV/r ± DSV discontinued 2 (0.7) 17 (1.8) 10 (0.8) 29 (4.9)
AEs related to RBV� 64 (23.8) 283 (30.5) N/A 347 (14.4)
RBV discontinued 4 (1.5) 57 (6.1) N/A 61 (5.1)��
RBV reduced/interrupted 31 (11.5) 146 (15.7) N/A 177 (14.8)��
AEs related to RBV 64 (23.8) 283 (30.5) N/A 347 (29.0)��
Abbreviations: AE, adverse event; OBV/PTV/r ± DSV ± RBV, ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin.
Values are presented as n (%).
� There were 56 serious AEs, 5 probably/possibly related to OBV/PTV/r + DSV + RBV, 10 with OBV/PTV/r + DSV and 7 with RBV.
�� Calculated over total of patients treated with RBV.
https://doi.org/10.1371/journal.pone.0225061.t004
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Therapy with DAA with OBV/PTV/r ± DSV ± RBV has been extensively studied in clinical
trials and observational studies and has shown high effectiveness, with overall SVR12 rates
ranging from 95% to 100%. Our findings in real-world clinical practice were comparable with
those in clinical trials [14, 22–26] and previous post-marketing studies [27, 28] that reported
SVR12 rates of�95% across different patient subgroups. A recent real-life study has even
shown the durability of the SVR response after 2 years following the EoT with OBV/PTV/
r ± DSV ± RBV [29].
The results of this study also showed that, although patients with HIV/HCV coinfection
(94.8% [95% CI: 92.1–96.8%]) had lower SVR12 rates than patients with HCV monoinfection
(97.0% [95% CI: 96.1–97.7%]), clinical effectiveness in the coinfected group, as measured by
SVR12, was statistically non-inferior to that of the monoinfected group. Our SVR12 rates are
comparable with those reported for patients with HCV monoinfection (94% [95% CI: 91.7–
96%]) and those with HIV/HCV coinfection (97% [95%CI: 95.7–99.4%]) with all-oral DAA
regimens in a recent real-life study conducted in a similar context in Spain [30].
Of note, from the 386 patients with HIV/HCV included in this study, only 20 did not
achieve SVR12 (5.2%, 6 with missing data). Patients with HIV/HCV with or without cirrhosis
treated with other DAAs have achieved high SVR12 rates, which shows that DAA regimens
are effective and well tolerated by patients coinfected with HIV/HCV with or without cirrho-
sis, as previously reported [16, 31].
Among our patients with GT1, SVR12 rates were similar to those observed in a real-world
study in a German cohort [28] and in a meta-analysis of the effectiveness of OBV/PTV/
r ± DSV ± RBV [27], which reported overall SVR12 rates above 95% for patients with GT1.
However, the SVR12 rates in our study for GT4 patients were somewhat lower than those
reported in those studies (>95%) [27, 28]. Moreover, in our study, only GT4 was predictive of
OBV/PTV/r ± RBV treatment failure, possibly because a higher percentage of GT4 patients
with compensated cirrhosis (20.3%) were treated off-label (OBV/PTV/r ± RBV 12 weeks;
OBV/PTV/r + DSV ± RBV 24 weeks) in comparison with patients with GT1b (2.6%) and
GT1a (15.3%). In addition, our GT4 group included a high percentage of patients with HIV/
HCV (38.0%) in whom SVR rates were generally lower than in patients with HCV. However,
in our study, coinfection with HIV was not an independent predictor of treatment failure.
Additionally, failure to achieve SVR12 in our population was mostly associated with reasons
not related to viral infection control, such as missing data or loss of follow-up, but not with
virologic failure. The combination of OBV/PTV/r ± DSV ± RBV was generally well tolerated.
In fact, only one in four patients (24.8%) reported an AE, slightly lower than those seen in clin-
ical studies (52% in the German study [28] and 77%–78% in clinical trials [32]), but similar to
the rates reported in a recent global study [33]. Nevertheless, the observational and retrospec-
tive nature of this study may have led to potential underreporting of AEs.
In our study, only 29 patients (4.9%) interrupted the OBV/PTV/r ± DSV regimen, while 61
patients (5.1%) treated with ribavirin abandoned prematurely. The most common treatment-
related AEs reported are similar to results obtained in clinical trials [14], with anemia being
the most frequent AE reported in the ribavirin-treated group. In addition, a slight decline in
the eGFR was recorded from baseline to 12 weeks post-treatment, but the mean reduction in
the eGFR was <10 mL/min/1.73m2, which is considered the minimum change that could be
associated with meaningful clinical significance.
From a methodological perspective, our study provides added value to previous observa-
tional studies, derived from the sample size and the particular method for patient selection to
obtain a broad and representative HCV and HIV/HCV population, randomly selected from a
large number of study sites in Spain. However, because of the real-world design of the study,
some general limitations of observational cohorts might also apply here. For example, the
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treatment regimen and duration were determined according to the criteria of the physician,
and the 9.1% of patients treated off-label were not independently analyzed, nor was this vari-
able included in the regression model analysis. Monitoring of patients during follow-up
(including laboratory assessment) was also conducted at the investigator’s discretion, resulting
in missing data for some patients. In addition, local practice discrepancies or data entry errors
might have occurred.
These results support and complement previous clinical and real-world data confirming
that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in patients with chronic
HCV monoinfection and HIV/HCV coinfection under routine practice conditions. In addi-
tion, our study provides an interesting insight into the outcomes of DAAs in Spain within the
experience of a well-articulated national strategic plan to tackle HCV, one of the main public
health problems in Spain.
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